Non Small Cell Lung Cancer (NSCLC) Clinical Trial
Official title:
Phase IA/IB of Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With Non Small Cell Lung Cancer or Malignant Pleural Mesothelioma
Background: Metronomic oral Vinorelbine has efficacy in metastatic NSCLC and malignant Pleural Mesothelioma, but all the studies published thus far were based upon a variety of empirical and possibly suboptimal schedules, with inconsistent results. Mathematical modeling showed by simulation that a new metronomic protocol could lead to a better safety and efficacy profile. Design: This phase Ia/Ib trial was designed to confirm safety (phase Ia) and evaluate efficacy (phase Ib) of a new metronomic oral vinorelbine schedule. Patient with metastatic NSCLC or malignant Pleural Mesothelioma, after failure of standard treatments, ECOG 0-2 and an adequate organ functions, will be eligible. Our mathematical PK-PD model suggested an alternative weekly D1, D2 and D4 innovative schedule (named Vinorelbine Theoretical Protocol) with a dynamic intake of 60, 30 and 60 mg, respectively. Trial recruitment is two-staged as 12 patients are planned to participate in the phase Ia, to confirm safety and consolidate the calibration of the average parameters of the model. Depending the phase Ia result, and after favorable decision of a consultative committee, the extension phase (phase Ib) will be an efficacy study and will include a number of 20 patients receiving the Optimal Vinorelbine Theoretical Protocol. The primary endpoint is the tolerance (assessed by CTC v4.0) for the phase Ia and the objective response according to RECIST 1.1 for the phase Ib. An ancillary study on circulating angiogenesis biomarkers will be a subproject of the trial. Discussion: this ongoing trial is the first to prospectively test a mathematical optimized schedule in metronomic chemotherapy. As such, this trial can be considered as a proof-of-concept study demonstrating the feasibility to run a computational-driven protocol to ensure an optimal efficacy/toxicity balance in patients with cancer.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01204099 -
Study of PX-866 and Docetaxel in Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04083599 -
GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT00148798 -
Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)
|
Phase 3 | |
| Recruiting |
NCT06026410 -
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02988817 -
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT01005797 -
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT00637910 -
Tarceva Italian Lung Optimization tRial
|
Phase 3 | |
| Active, not recruiting |
NCT03447678 -
Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.
|
Phase 2 | |
| Completed |
NCT02456246 -
Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT
|
N/A | |
| Terminated |
NCT01741155 -
Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
|
Phase 2 | |
| Completed |
NCT02014324 -
Single Scope Staging of Lung Cancer With Endosonography
|
N/A | |
| Completed |
NCT01594398 -
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT01323062 -
Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT04772989 -
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT01702844 -
Single Arm on the Tolerability of Weekly Nab-paclitaxel
|
Phase 2 | |
| Completed |
NCT00492206 -
Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC
|
Phase 2 | |
| Completed |
NCT00820417 -
Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib
|
Phase 1 | |
| Completed |
NCT02639026 -
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
|
Phase 1 | |
| Completed |
NCT01282437 -
Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC
|
Phase 3 | |
| Active, not recruiting |
NCT04721015 -
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
|
Phase 1 |